Comparisons of the effectiveness of Covid-19 vaccines are very frequent. However, each immunizing agent has a specific technology, a specific design and was tested in different contexts (countries, populations and different times). Therefore, any comparison between the effectiveness of vaccines is wrong, explains Ana Marisa Chudzinski-Tavassi, director of innovation at Instituto Butantan and at the Centre of Excellence in New Target Discovery (CENTD). CoronaVac, a vaccine from Butantan and Sinovac, uses inactivated virus technology, widely studied and consolidated in the world.
At the CoronaVac Symposium, to be held on the 7th, 8th and 9th of December, Brazilian and foreign researchers will present to society data from dozens of clinical studies on the effectiveness of the immunizing agent. The event is an initiative of Butantan and Sinovac and brings together specialists from Brazil, the United States, Turkey, Chile, China and Spain.
According to Ana Marisa, the effectiveness of a vaccine can be defined in several ways. “If we think about efficacy to prevent deaths, for example, all the vaccines that were and are being administered in the population are highly effective and were able to reduce the number of deaths. Just look at the graphics,” she says.
See this and other videos in our playlist
Visit the CoronaVac Symposium website